- Home
- DXLG vs IXHL Comparison
DXLG vs IXHL Comparison
Compare DXLG & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DXLG | IXHL |
|---|---|---|
| Founded | 1976 | 2001 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.6M | 49.1M |
| IPO Year | 1987 | N/A |
Fundamental Metrics
Financial Performance| Metric | DXLG | IXHL |
|---|---|---|
| Price | $1.13 | $0.43 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $2.50 | N/A |
| AVG Volume (30 Days) | 72.3K | ★ 23.8M |
| Earning Date | 12-11-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $447,744,000.00 | $12,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.95 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.88 | $0.08 |
| 52 Week High | $3.10 | $2.25 |
Technical Indicators
Market Signals| Indicator | DXLG | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 62.42 | 59.02 |
| Support Level | $0.90 | $0.35 |
| Resistance Level | $1.23 | $0.50 |
| Average True Range (ATR) | 0.08 | 0.03 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 68.57 | 68.63 |
Price Performance
Historical ComparisonAbout DXLG Destination XL Group Inc.
Destination XL Group Inc is a retailer of branded and Tall men's clothing and shoes in the United States. It also sells products across the world. The company sells its products under the trade names Destination XL, DXL, DXL Men's Apparel, DXL outlets, Casual Male XL, and Casual Male XL outlets. The company has two principal operating segments: Store, and Direct business.
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.